Twenty First Annual Blood-Brain Barrier Consortium Meeting in collaboration with the International Brain Barriers Society

March 19-21, 2015
Skamania Lodge, Stevenson, WA

THURSDAY, MARCH 19th
MORNING SESSION (CASCADE LOCKS)

8:00 Continental Breakfast

**Consensus Conference on Platinum Toxicities in Children and Chemoprotection**

8:30 Welcome  
*Conference Co-Chairs:*  
Kristin Knight  
Portland, OR  
Susan Lindemulder  
Portland, OR

8:35 Mission and Charge  
*Moderators:*  
Lori Minasian  
Rockville, MD  
Lindsay Frazier  
Boston, MA

8:45 Past, Present and Future Perspective of Otoprotectants  
*Penelope Brock*  
London, UK

9:15 Decision Making, Values Clarification and Relevance to Otoprotection  
*Lillian Sung*  
Toronto, ON

9:45 Results of Recently Completed Pediatric Clinical Trials  
*Co-Chairs:*  
David Freyer  
Los Angeles, CA  
Bruce Morland  
Birmingham, UK

10:30 Break

10:45 Mechanisms of Ototoxicity and Genomic Modulation  
*Co-Chairs:*  
Peter Steyger  
Portland, OR  
Kathleen Campbell  
Springfield, IL

11:30 Otoprotectants  
*Co-Chairs:*  
Louis Rapkin  
Atlanta, GA  
Leslie Muldoon  
Portland, OR

12:15 Buffet Lunch and Keynote Presentations

Patient/Parent Interview  
*Interviewer:*  
Archie Bleyer  
Bend, OR  
*Subjects:*  
The Cahana Family  
Portland, OR

Improving Outcomes for Pediatric Cancer Patients  
*Lori Minasian*  
Rockville, MD

1:30 Break
Consensus Conference on Platinum Toxicities in Children and Chemoprotection (cont.)

**AFTERNOON SESSION**

1:45  Assessment of Ototoxicity

   **Co-Chairs:** Kay Chang  
   Palo Alto, CA  
   Kristin Knight  
   Portland, OR

2:30  Options for Study Design

   **Moderator:** Mark Krailo  
   Los Angeles, CA

3:45  Initial Small Group Discussions

   **Group 1:** Stand alone Ototoxicity Trial  
   (Baker)  
   **Leader:** David Freyer

   **Group 2:** Ototoxicity Embedded in Therapeutic Trial  
   (Rainier)  
   **Leader:** Bruce Morland

5:30  Adjourn

**EVENING SESSION**

6:30  Dinner

   **Welcome:**  
   **Edward Neuwelt**  
   Portland, OR  
   **Les Drewes**  
   Duluth, MN

   **Keynote Addresses**

   “Benefit: Risk Considerations in the Development of Supportive Care Products in Cancer: The FDA Perspective”  
   **Greg Reaman**  
   Washington, DC

   “Clinical Trial Challenges: Development of Chemoprotectants for Children with Cancer”  
   **Peter Adamson**  
   Philadelphia, PA

8:00  Dessert and Poster Session (Adams)
### FRIDAY, MARCH 20th  
**MORNING SESSION**  
*(CASCADE LOCKS)*

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>6:45</td>
<td>Continental Breakfast</td>
</tr>
</tbody>
</table>
| 7:00  | Industry Perspective: Additional Considerations  
  *Kathleen Campbell, Per Gjorstrup, Franck Rousseau* |
| 7:30  | Small groups reconvene and create recommendations                   |
| 9:15  | Groups reconvene and present results                               |
| 9:45  | Consensus and next steps                                           |
| 10:15 | Otoprotection Consensus Conference Adjourns                          |
| 10:15 | **Break**                                                           |
| 10:30 | **Blood-Brain Barrier Consortium Discussion** - all registrants are welcome to attend|
| 12:15 | **Group Photo**                                                     |
| 12:30 | **Buffet Lunch**                                                    | *(MAIN DINING HALL)* |

### AFTERNOON SESSION  
*(CASCADE LOCKS)*

#### Translational Scientists’ Views of Imaging and the Neurovascular Unit

*Moderator: Les Drewes  
Duluth, MN*

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
</table>
| 1:00  | Two photon microscopy  
  *Jeffrey Iliff  
Portland, OR* |
| 1:20  | Imaging the brain barriers  
  *Danica Stanimirovic  
Ottowa, Canada* |
| 1:40  | MRI vs. PET: preclinical and clinical advances  
  *Ken Krohn  
Seattle, WA* |
| 2:00  | **Imaging issues from the perspective of the Blood-Brain Barrier Program** |

*Moderator: Les Drewes*

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
</table>
| 2:00  | Anatomic imaging with ferumoxytol and FDA submission  
  *Bronwyn Hamilton  
Portland, OR* |
| 2:20  | DSC imaging +/- leakage correction; DSC imaging pre- and post- Avastin  
  *Joao Prola-Netto  
Portland, OR* |
| 2:40  | Steady state imaging  
  *Csanad Varallyay  
Portland, OR* |
Translational Scientists’ Views of Imaging and the Neurovascular Unit (cont.)

3:00  Pseudoprogression vs. disease progression with ferumoxytol  Seymour Gahramanov  
      Albuquerque, NM  
3:20  Advances using ferumoxytol in children  Heike Daldrup-Link  
      Palo Alto, CA  
3:40  Permeability in cerebrovascular ischemic disease  Christopher d’Esterre  
      Calgary, Canada  
4:00  Break  
4:15  Breakout Group Discussions: Basic Scientists and Clinicians Discuss Case Examples of Clinical Dilemmas in Neuroimaging  

3:00  Pseudoprogression vs. disease progression with ferumoxytol  
5:00  Advances using ferumoxytol in children  
6:00  Permeability in cerebrovascular ischemic disease  

4:00  Break  
4:15  Breakout Group Discussions: Basic Scientists and Clinicians Discuss Case Examples of Clinical Dilemmas in Neuroimaging  

Evening Session

6:00  Dinner (Columbia River Gorge Interpretive Center)  
Piano performance by Zora Mihailovich followed by dinner  
8:00  Dessert and Poster Session (Adams)
6:45  Continental Breakfast

7:00  Funding Opportunities Roundtable:  
Francesca Bosetti (NINDS), Roy Wu (NCI), Paula Jacobs (NCI)

7:30  Getting To, Through and Beyond the FDA

  **Moderators:**  
  Paula Jacobs  
  Bethesda, MD  
  Sandra Shotwell  
  Portland, OR  
  Joseph Bubalo  
  Portland, OR

### Imaging the Neurovascular Unit: Permeability, Blood Volume, and Functional Imaging

**Moderator:**  
Mauricio Castillo  
Chapel Hill, NC

<table>
<thead>
<tr>
<th>Time</th>
<th>Topic</th>
<th>Presenter</th>
<th>Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>8:00</td>
<td>Leaky blood-brain barrier and pericytes: implications for neurodegeneration and cognitive impairment</td>
<td>Berislav Zlokovic</td>
<td>Los Angeles, CA</td>
</tr>
<tr>
<td>8:20</td>
<td>Resting state fMRI</td>
<td>Haris Sair</td>
<td>Boston, MA</td>
</tr>
<tr>
<td>8:40</td>
<td>Imaging permeability: general concepts and clinical importance</td>
<td>Yueh Lee</td>
<td>Chapel Hill, NC</td>
</tr>
<tr>
<td>9:00</td>
<td>BBB/NVU, permeability, and cognition disorders</td>
<td>Saeid Taheri</td>
<td>Charleston, SC</td>
</tr>
<tr>
<td>9:20</td>
<td>New and alternative techniques for tumor permeability assessment</td>
<td>Rajan Jain</td>
<td>New York City, NY</td>
</tr>
<tr>
<td>9:40</td>
<td>Break</td>
<td></td>
<td></td>
</tr>
<tr>
<td>9:50</td>
<td>Permeability in pediatric brain tumors</td>
<td>Ashok Panigrahy</td>
<td>Pittsburgh, PA</td>
</tr>
<tr>
<td>10:10</td>
<td>Permeability in cerebral inflammatory disease</td>
<td>Daniel Reich</td>
<td>Bethesda, MD</td>
</tr>
<tr>
<td>10:30</td>
<td>Imaging Roundtable</td>
<td><strong>Moderators:</strong> Maurice Castillo, Francesca Bosetti, Yueh Lee, William Strauss</td>
<td></td>
</tr>
<tr>
<td>11:00</td>
<td>Key Highlights from the Neuroimaging Breakout Group Discussions</td>
<td><strong>Moderators:</strong> Edward Neuwelt, Ken Krohn</td>
<td></td>
</tr>
<tr>
<td>11:30</td>
<td>Meeting Wrap-up and Future Directions</td>
<td></td>
<td></td>
</tr>
<tr>
<td>11:45</td>
<td>Adjourn</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**REMINDER:** Please complete the meeting evaluation form in your packet before 12 noon Saturday and submit at the Registration Table. This is required by the NIH R13 grant.